{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:29:19Z","timestamp":1786580959523,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Hangzhou Zhongmeihuadong Pharmaceutical Co., LTD"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02904-0","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:02:09Z","timestamp":1786579329000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study"],"prefix":"10.1038","volume":"11","author":[{"given":"Jia","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwen","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongrui","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0029-6879","authenticated-orcid":false,"given":"Chengzhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panwen","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junguo","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangsheng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghui","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongqing","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingxun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyin","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meili","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shundong","family":"Cang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezhen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhixiang","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaonan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6958-0766","authenticated-orcid":false,"given":"Caicun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"2904_CR1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.21147\/j.issn.1000-9604.2022.03.03","volume":"34","author":"National Health Commission of the People\u2019s Republic of China","year":"2022","unstructured":"National Health Commission of the People\u2019s Republic of China National guidelines for diagnosis and treatment of lung cancer 2022 in China (English version). Chin. J. Cancer Res. 34, 176\u2013206 (2022).","journal-title":"Chin. J. Cancer Res."},{"key":"2904_CR2","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/cac2.12359","volume":"42","author":"P Chen","year":"2022","unstructured":"Chen, P., Liu, Y., Wen, Y. & Zhou, C. Non-small cell lung cancer in China. Cancer Commun. 42, 937\u2013970 (2022).","journal-title":"Cancer Commun."},{"key":"2904_CR3","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han, B. et al. Cancer incidence and mortality in China, 2022. J. Natl. Cancer Cent. 4, 47\u201353 (2024).","journal-title":"J. Natl. Cancer Cent."},{"key":"2904_CR4","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2904_CR5","first-page":"2892","volume":"5","author":"A Midha","year":"2015","unstructured":"Midha, A., Dearden, S. & McCormack, R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am. J. Cancer Res. 5, 2892\u20132911 (2015).","journal-title":"Am. J. Cancer Res."},{"key":"2904_CR6","doi-asserted-by":"publisher","first-page":"e1070","DOI":"10.1634\/theoncologist.2018-0572","volume":"24","author":"S Wen","year":"2019","unstructured":"Wen, S. et al. Genomic signature of driver genes identified by target next-generation sequencing in Chinese non-small cell lung cancer. Oncologist 24, e1070\u2013e1081 (2019).","journal-title":"Oncologist"},{"key":"2904_CR7","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.3390\/cancers14102519","volume":"14","author":"R Kitadai","year":"2022","unstructured":"Kitadai, R. & Okuma, Y. Treatment strategies for non-small cell lung cancer harboring common and uncommon EGFR mutations: drug sensitivity based on exon classification, and structure-function analysis. Cancers 14, 2519 (2022).","journal-title":"Cancers"},{"key":"2904_CR8","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947\u2013957 (2009).","journal-title":"N. Engl. J. Med."},{"key":"2904_CR9","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1200\/JCO.2010.33.4235","volume":"29","author":"M Fukuoka","year":"2011","unstructured":"Fukuoka, M. et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin\/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 29, 2866\u20132874 (2011).","journal-title":"J. Clin. Oncol."},{"key":"2904_CR10","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist, L. V. et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol. 31, 3327\u20133334 (2013).","journal-title":"J. Clin. Oncol."},{"key":"2904_CR11","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/annonc\/mdv270","volume":"26","author":"YL Wu","year":"2015","unstructured":"Wu, Y. L. et al. First-line erlotinib versus gemcitabine\/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann. Oncol. 26, 1883\u20131889 (2015).","journal-title":"Ann. Oncol."},{"key":"2904_CR12","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","volume":"28","author":"YK Shi","year":"2017","unstructured":"Shi, Y. K. et al. First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann. Oncol. 28, 2443\u20132450 (2017).","journal-title":"Ann. Oncol."},{"key":"2904_CR13","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/S1470-2045(17)30608-3","volume":"18","author":"YL Wu","year":"2017","unstructured":"Wu, Y. L. et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 18, 1454\u20131466 (2017).","journal-title":"Lancet Oncol."},{"key":"2904_CR14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria, J. C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113\u2013125 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2904_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382, 41\u201350 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2904_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100115","volume":"6","author":"K Ito","year":"2021","unstructured":"Ito, K. et al. A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903. ESMO Open 6, 100115 (2021).","journal-title":"ESMO Open"},{"key":"2904_CR17","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","volume":"10","author":"Y Shi","year":"2022","unstructured":"Shi, Y. et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Lancet Respir. Med. 10, 1019\u20131028 (2022).","journal-title":"Lancet Respir. Med."},{"key":"2904_CR18","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/JCO.21.02641","volume":"40","author":"S Lu","year":"2022","unstructured":"Lu, S. et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations. J. Clin. Oncol. 40, 3162\u20133171 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2904_CR19","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S2213-2600(23)00183-2","volume":"11","author":"S Lu","year":"2023","unstructured":"Lu, S. et al. Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study. Lancet Respir. Med. 11, 905\u2013915 (2023).","journal-title":"Lancet Respir. Med."},{"key":"2904_CR20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40265-020-01441-6","volume":"81","author":"TS Mok","year":"2021","unstructured":"Mok, T. S. et al. Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. Drugs 81, 257\u2013266 (2021).","journal-title":"Drugs"},{"key":"2904_CR21","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1200\/JCO.2005.00.992","volume":"23","author":"T Mitsudomi","year":"2005","unstructured":"Mitsudomi, T. et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23, 2513\u20132520 (2005).","journal-title":"J. Clin. Oncol."},{"key":"2904_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.lungcan.2015.02.004","volume":"88","author":"T Fukuhara","year":"2015","unstructured":"Fukuhara, T. et al. Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. Lung Cancer 88, 181\u2013186 (2015).","journal-title":"Lung Cancer"},{"key":"2904_CR23","first-page":"100322","volume":"3","author":"SK Chan","year":"2022","unstructured":"Chan, S. K., Choi, H. C. & Lee, V. H. Overall survival benefits of first-line treatments for asian patients with advanced EGFR-mutated NSCLC harboring L858R mutation: a systematic review and network meta-analysis. JTO Clin. Res. Rep. 3, 100322 (2022).","journal-title":"JTO Clin. Res. Rep."},{"key":"2904_CR24","doi-asserted-by":"publisher","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","volume":"29","author":"D Westover","year":"2018","unstructured":"Westover, D., Zugazagoitia, J., Cho, B. C., Lovly, C. M. & Paz-Ares, L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann. Oncol. 29, i10\u2013i19 (2018).","journal-title":"Ann. Oncol."},{"key":"2904_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.lungcan.2019.09.017","volume":"137","author":"ACZ Gelatti","year":"2019","unstructured":"Gelatti, A. C. Z., Drilon, A. & Santini, F. C. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Lung Cancer 137, 113\u2013122 (2019).","journal-title":"Lung Cancer"},{"key":"2904_CR26","doi-asserted-by":"publisher","first-page":"4926","DOI":"10.3390\/cancers13194926","volume":"13","author":"D Reita","year":"2021","unstructured":"Reita, D. et al. Molecular mechanism of EGFR-TKI resistance in EGFR-mutated non-small cell lung cancer: application to biological diagnostic and monitoring. Cancers 13, 4926 (2021).","journal-title":"Cancers"},{"key":"2904_CR27","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41392-021-00773-3","volume":"6","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib\/II efficacy and biomarker study. Signal Transduct. Target Ther. 6, 374 (2021).","journal-title":"Signal Transduct. Target Ther."},{"key":"2904_CR28","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1002\/cac2.12456","volume":"43","author":"P Wang","year":"2023","unstructured":"Wang, P. et al. A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations. Cancer Commun. 43, 1059\u20131063 (2023).","journal-title":"Cancer Commun."},{"key":"2904_CR29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","volume":"17","author":"K Park","year":"2016","unstructured":"Park, K. et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 17, 577\u2013589 (2016).","journal-title":"Lancet Oncol."},{"key":"2904_CR30","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/annonc\/mdw611","volume":"28","author":"L Paz-Ares","year":"2017","unstructured":"Paz-Ares, L. et al. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Ann. Oncol. 28, 270\u2013277 (2017).","journal-title":"Ann. Oncol."},{"key":"2904_CR31","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/j.jtho.2025.06.030","volume":"20","author":"SH Lee","year":"2025","unstructured":"Lee, S. H. et al. Lazertinib versus osimertinib in previously untreated EGFR-mutant advanced NSCLC: a randomized, double-blind, exploratory analysis from MARIPOSA. J. Thorac. Oncol. 20, 1655\u20131668 (2025).","journal-title":"J. Thorac. Oncol."},{"key":"2904_CR32","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1200\/JCO.2017.74.7576","volume":"36","author":"SS Ramalingam","year":"2018","unstructured":"Ramalingam, S. S. et al. Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer. J. Clin. Oncol. 36, 841\u2013849 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2904_CR33","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11523-021-00794-6","volume":"16","author":"Y Cheng","year":"2021","unstructured":"Cheng, Y. et al. Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study. Target Oncol. 16, 165\u2013176 (2021).","journal-title":"Target Oncol."},{"key":"2904_CR34","doi-asserted-by":"publisher","first-page":"6644","DOI":"10.1158\/1078-0432.CCR-19-1126","volume":"25","author":"JE Gray","year":"2019","unstructured":"Gray, J. E. et al. Tissue and plasma EGFR mutation analysis in the FLAURA trial: osimertinib versus comparator EGFR tyrosine kinase inhibitor as first-line treatment in patients with EGFR-mutated advanced non-small cell lung cancer. Clin. Cancer Res. 25, 6644\u20136652 (2019).","journal-title":"Clin. Cancer Res."},{"key":"2904_CR35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S2213-2600(24)00417-X","volume":"13","author":"Y Shi","year":"2025","unstructured":"Shi, Y. et al. Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (REZOR): a multicentre, double-blind, randomised, phase 3 study. Lancet Respir. Med. 13, 327\u2013337 (2025).","journal-title":"Lancet Respir. Med."},{"key":"2904_CR36","doi-asserted-by":"publisher","first-page":"108710","DOI":"10.1016\/j.lungcan.2025.108710","volume":"207","author":"Y Yu","year":"2025","unstructured":"Yu, Y., Pan, Y., Zhou, J., Mu, S. & Lu, S. Dacomitinib in the treatment of EGFR-mutated non-small cell lung cancer with brain metastases: an open-label, multicenter, phase II study. Lung Cancer 207, 108710 (2025).","journal-title":"Lung Cancer"},{"key":"2904_CR37","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo, M. et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380\u20132388 (2010).","journal-title":"N. Engl. J. Med."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02904-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02904-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02904-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:02:11Z","timestamp":1786579331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02904-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2904"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02904-0","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"X.S., B.Y., C.Z., J.C. and J.X. are employees of Hangzhou Zhongmei Huadong Pharmaceutical Company. The other authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This study collected blood samples from the human subjects. This study was approved by the institutional review board\/independent ethics committee of the participating centers, which are detailed in Appendix 1 (Supplementary Materials). Written informed consent were obtained from all participants before enrollment in the study.","order":2,"name":"Ethics","label":"Ethical approval and consent to particpate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"324"}}